Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | LIPE | Q05469 | 4/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.38 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.38 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9960807 | 0.90 | LMNA (0.47) | RAB9ASMN1; SMN2NPC1MEN1KMT2A | |
| SCHEMBL9960717 | 0.90 | RAB9A (0.36) | RAB9ASMN1; SMN2NPC1MEN1KMT2A | |
| SCHEMBL9960651 | 0.87 | HSD17B1 (0.41) | RAB9ASMN1; SMN2NPC1MEN1KMT2A | |
| SCHEMBL9960675 | 0.86 | RAB9A (0.35) | RAB9ASMN1; SMN2NPC1MEN1KMT2A | |
| SCHEMBL9960584 | 0.86 | CHRNB2 (0.42) | RAB9ASMN1; SMN2NPC1MEN1KMT2A | |
| SCHEMBL9960782 | 0.86 | GPBAR1 (0.39) | RAB9ASMN1; SMN2NPC1MEN1KMT2A | |
| SCHEMBL9960629 | 0.85 | RAB9A (0.42) | RAB9ANPC1KMT2AALDH1A1LMNA | |
| SCHEMBL9960710 | 0.85 | HSD17B2 (0.44) | — | |
| SCHEMBL9960746 | 0.83 | ALDH1A1 (0.45) | SMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL9960699 | 0.83 | LIPE (0.39) | RAB9ASMN1; SMN2NPC1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2655323-B1 | INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES | LEO LABORATORIES LTD (IE) | 2017-12-20 | — | — | EP | claimed |
| US-20170217910-A1 | INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES | LEO LABORATORIES LIMITED (IE) | 2017-08-03 | — | — | US | claimed |
| US-9708286-B2 | Ingenol-3-acylates III and ingenol-3-carbamates | LEO LABORATORIES LIMITED (IE) | 2017-07-18 | — | — | US | claimed |
| CN-104529827-B | Ingenol-3-acylate III and ingenol-3-carbamate | 利奥实验室有限公司 | 2016-08-24 | — | — | CN | claimed |
| US-20150291551-A1 | INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES | LEO LABORATORIES LIMITED (IE) | 2015-10-15 | — | — | US | claimed |
| CN-104529827-A | Ingenol-3-acylates III and ingenol-3-carbamates | LEO PHARMA AS | 2015-04-22 | — | — | CN | claimed |
| US-20140303150-A1 | INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES | LEO LABORATORIES LIMITED (IE) | 2014-10-09 | — | — | US | claimed |
| CN-103402977-A | Ingenol-3-acylate III and Ingenol-3-carbamate | LEO PHARMA AS | 2013-11-20 | — | — | CN | claimed |
| EP-2655323-A1 | INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES | LEO LABORATORIES LIMITED (IE) | 2013-10-30 | — | — | EP | claimed |
| WO-2012083953-A1 | INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES | LEO PHARMA A/S (DK) | 2012-06-28 | — | — | WO | claimed |
| EP-2655323-B1 | INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES | LEO LABORATORIES LTD (IE) | 2017-12-20 | — | — | EP | disclosed |
| EP-3004036-B1 | METHODS OF SYNTHESIS OF INGENOL AND INTERMEDIATES THEREOF | LEO LABORATORIES LTD (IE) | 2017-11-22 | — | — | EP | disclosed |
| US-20170217910-A1 | INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES | LEO LABORATORIES LIMITED (IE) | 2017-08-03 | — | — | US | disclosed |
| US-9708286-B2 | Ingenol-3-acylates III and ingenol-3-carbamates | LEO LABORATORIES LIMITED (IE) | 2017-07-18 | — | — | US | disclosed |
| CN-104529827-B | Ingenol-3-acylate III and ingenol-3-carbamate | 利奥实验室有限公司 | 2016-08-24 | — | — | CN | disclosed |
| WO-2014191457-A1 | METHODS OF SYNTHESIS OF INGENOL AND INTERMEDIATES THEREOF | LEO LABORATORIES LIMITED (IE) | 2014-12-04 | — | — | WO | disclosed |
| US-20140303150-A1 | INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES | LEO LABORATORIES LIMITED (IE) | 2014-10-09 | — | — | US | disclosed |
| CN-103402977-A | Ingenol-3-acylate III and Ingenol-3-carbamate | LEO PHARMA AS | 2013-11-20 | — | — | CN | disclosed |
| EP-2655323-A1 | INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES | LEO LABORATORIES LIMITED (IE) | 2013-10-30 | — | — | EP | disclosed |
| WO-2012083953-A1 | INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES | LEO PHARMA A/S (DK) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170217910-A1 | INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES | RXRB, RXRA, RXRG | RAB9A 908/4885SMN1; SMN2 4677/4885NPC1 1253/4885 |
| US-20150291551-A1 | INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES | RXRB, RXRA, RXRG | RAB9A 908/4885SMN1; SMN2 4677/4885NPC1 1253/4885 |
| US-20140303150-A1 | INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES | RXRB, RXRA, RXRG | RAB9A 908/4885SMN1; SMN2 4677/4885NPC1 1253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.